Introgen Therapeutics' INGN 241 Exhibits Promise in Anti-Angiogenic Cancer Therapy

Introgen Therapeutics, Inc. (INGN) has unveiled data on a novel mechanism of action for its therapy, INGN 241, which targets the formation of new blood vessels in tumors, a process called angiogenesis. This mechanism is crucial for tumors to establish a sufficient supply of oxygen and nutrients, leading to tumor cell death and inhibition of tumor growth. Introgen's research demonstrates that INGN 241 acts as an antiangiogenic agent by inhibiting the production of vascular endothelial growth factor (VEGF) protein, a key mediator of angiogenesis. These findings are significant, as they suggest a direct approach to inhibiting angiogenesis, unlike existing treatments like Avastin that target VEGF function by blocking its receptor.

Key Takeaways:

• INGN 241 has been shown to inhibit the formation of new blood vessels in tumors by blocking the production of VEGF protein.
• This mechanism is critical for tumors to establish a sufficient supply of oxygen and nutrients, leading to tumor cell death and inhibition of tumor growth.
• INGN 241 demonstrates a more direct approach to inhibiting angiogenesis compared to existing treatments like Avastin.
• Furthermore, INGN 241 acts through multiple mechanisms to suppress tumor growth, stimulate antitumor immunity, and sensitize tumors to radiation and chemotherapy.
• The therapy has been shown to significantly inhibit VEGF expression and activity in human prostate cancer cell lines.
• Introgen Therapeutics, Inc. is a biopharmaceutical company focused on developing targeted molecular therapies for cancer and other diseases.

Statistics:

• VEGF protein production was inhibited by 70% in human prostate cancer cell lines treated with INGN 241.
• The study demonstrated a significant correlation between INGN 241 treatment and inhibition of molecular pathways required for VEGF gene turn-on.
• Introgen Therapeutics, Inc. has developed multiple candidates targeting angiogenesis and other aspects of cancer biology.

Sources:

• Molecular Therapy
• Introgen Therapeutics, Inc.
• University of Texas M. D. Anderson Cancer Center
• Avastin
• U.S. Food and Drug Administration